Novo Nordisk

Pharma's pandemic reputation gains score a 'most-improved' medal in annual ranking
Pharma's pandemic reputation gains score a 'most-improved' medal in annual ranking
Fierce Pharma
reputation
pharma industry
Sanofi
Novo Nordisk
Roche
Eli Lilly
Bristol Myers Squibb
Flag link:
Big pharma freshens up
Big pharma freshens up
EP Vantage
Merck
Bristol Myers Squibb
Astellas
Novo Nordisk
AbbVie
Sanofi
Flag link:
FDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion Application
FDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion Application
Benzinga
Novo Nordisk
FDA
diabetes
semaglutide
RTF letters
Flag link:
Gilead, Novo Nordisk push NASH cocktail deeper into the clinic
Gilead, Novo Nordisk push NASH cocktail deeper into the clinic
Fierce Biotech
Gilead Sciences
Novo Nordisk
NASH
R&D
Flag link:
GSK, Novo and Roche meds hit pandemic potholes while Dupixent, Humira stood strong: analysts
GSK, Novo and Roche meds hit pandemic potholes while Dupixent, Humira stood strong: analysts
Fierce Pharma
COVID-19
pandemic
GSK
Novo Nordisk
Roche
Flag link:
Lilly has its Ozempic-beating data from a head-to-head diabetes trial. Should Novo Nordisk be worried?
Lilly has its Ozempic-beating data from a head-to-head diabetes trial. Should Novo Nordisk be worried?
Fierce Pharma
Eli Lilly
tirzepatide
diabetes
Ozempic
Novo Nordisk
clinical trials
Flag link:
Lilly's tirzepatide beats Novo's semaglutide in diabetes phase 3, but another study muddies picture
Lilly's tirzepatide beats Novo's semaglutide in diabetes phase 3, but another study muddies picture
Fierce Biotech
Eli Lilly
Novo Nordisk
tirzepatide
semaglutide
type 2 diabetes
clinical trials
Flag link:
Watch out, Novo Nordisk. Lilly's new dual action diabetes med could pressure Ozempic: analyst
Watch out, Novo Nordisk. Lilly's new dual action diabetes med could pressure Ozempic: analyst
Fierce Pharma
Eli Lilly
tirzepatide
Novo Nordisk
Ozempic
diabetes
Flag link:
Novo Nordisk's blockbuster diabetes drug blows the doors off in obesity, proving highly effective in driving weight loss
Novo Nordisk's blockbuster diabetes drug blows the doors off in obesity, proving highly effective in driving weight loss
Endpoints
Novo Nordisk
semaglutide
obesity
Flag link:
Novo Nordisk plots $1.3B in spending as it expands API production—and advances new oral meds
Novo Nordisk plots $1.3B in spending as it expands API production—and advances new oral meds
Fierce Pharma
Novo Nordisk
drug manufacturing
APIs
Flag link:
Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
Yahoo/Global Newswire
Novo Nordisk
FDA
Ozempic
type 2 diabetes
semaglutide
Flag link:
Pharma TV ad spenders blow up December with spendiest month of 2020
Pharma TV ad spenders blow up December with spendiest month of 2020
Fierce Pharma
television ads
AbbVie
Humira
Novo Nordisk
DTC ads
Flag link:
Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit
Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit
Pharmaforum
Novo Nordisk
Dicerna
gene silencing
liver disease
Flag link:
Novo takes the plunge in Alzheimer’s
Novo takes the plunge in Alzheimer’s
EP Vantage
Novo Nordisk
Rybelsus
Alzheimer's disease
Flag link:
Novo invests in Hemab, a company going against the hemophilia gene therapy grain with a plan for bispecifics
Novo invests in Hemab, a company going against the hemophilia gene therapy grain with a plan for bispecifics
Endpoints
Novo Nordisk
Novo Holdings
Hemab
hemophilia
Flag link:
Novo Nordisk to end 340B discounts on drugs dispensed at community pharmacies
Novo Nordisk to end 340B discounts on drugs dispensed at community pharmacies
Beckers Hospital Review
Novo Nordisk
340B
hospitals
Flag link:
Gilead and Novo plot next steps after trial data from NASH combo
Gilead and Novo plot next steps after trial data from NASH combo
Pharmaforum
Gilead Sciences
Novo Nordisk
NASH
clinical trials
semaglutide
cilofexor
firsocostat
Flag link:
Novo Nordisk to boost pill-form diabetic drugs with $1.8 billion deal
Novo Nordisk to boost pill-form diabetic drugs with $1.8 billion deal
Reuters
Novo Nordisk
M&A
Emisphere
pill technology
diabetes
Flag link:
AASLD 2020 – Nash updates from Novo and Inventiva in focus
AASLD 2020 – Nash updates from Novo and Inventiva in focus
EP Vantage
NASH
Novo Nordisk
Gilead Sciences
Inventiva
AASLD
selonsertib
Flag link:
Novo Nordisk quietly nabs a rare 'breakthrough' status in NASH for its cash cow
Novo Nordisk quietly nabs a rare 'breakthrough' status in NASH for its cash cow
Endpoints
Novo Nordisk
earnings
NASH
semaglutide
breakthrough therapy
FDA
Flag link:

Pages